about
High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphomaComparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphomaHigh-dose chemotherapy followed by autologous stem cell transplantation for refractory/relapsed Hodgkin lymphoma patientsChemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphomaComparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphomaChemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin LymphomaRecent advances in the management of Hodgkin lymphomaCancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers.Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studiesRole of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implicationsCrystal structure of DNA-bound Co(III){middle dot}bleomycin B2: Insights on intercalation and minor groove bindingAdvances in the treatment of relapsed or refractory Hodgkin's lymphomaPD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaComparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.Clinical Features and Prognostic Factors of Hodgkin's Lymphoma: A Single Center Experience.Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment.The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.Primary pulmonary Hodgkin's lymphoma.Hodgkin lymphoma at the paediatric oncology unit of gabriel touré teaching hospital, bamako, mali: 5-year experienceIncreased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat.A nationwide study of aspirin, other non-steroidal anti-inflammatory drugs, and Hodgkin lymphoma risk in Denmark.Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic eraPhase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaRadiation exposure and mortality risk from CT and PET imaging of patients with malignant lymphoma.Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.Survivorship care planning after participation in communication skills training intervention for a consultation about lymphoma survivorship.Hodgkin's lymphoma: molecular targets and novel treatment strategies.A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy.Novel small-molecule therapy of Hodgkin lymphoma.Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaClinical perspectives in lymphoma.Protocol for a cluster randomised trial of a communication skills intervention for physicians to facilitate survivorship transition in patients with lymphoma.Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma.Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-upTreatment of Hodgkin's disease: a twenty-year follow-up of patients at a center in Korea.Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphomaEconomic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.Whole-body diffusion-weighted imaging for staging malignant lymphoma in children.
P2860
Q24201885-91935459-2CA8-4932-86FE-7C8D0F1165A7Q24234975-2751B2EF-A66B-4DF8-9280-2B9651F3C82EQ24235563-FB2C9048-14A2-4CED-978D-CDF64E25D168Q24236589-6DA6DA66-9F8F-4937-8FB2-982868FF8BBCQ24240697-B21A67D4-9148-4ED8-9DFC-D814B7201503Q24243379-8F94AAB8-C67A-4B20-9549-E28D5BFE0FB9Q26751214-CAF4C590-A250-4766-B707-89E3293DCCB8Q26830028-EDCB5DC2-F26D-40C3-8C71-241D1E4B56F1Q27009307-35DAF00A-C3AB-479F-9A8A-87835CCE154EQ27011510-2B2B4DEA-9974-4301-881D-1C641C60C452Q27650149-6B72CD6D-3947-4711-93D6-1B30F60C7B72Q27694504-8693A60F-112B-48D7-872F-11555F44153EQ29620878-748B57BB-8140-452C-8981-ACD52DCD0D3CQ33442092-A4C95CD4-BE88-466C-8574-BEA56434D17DQ33974210-13DA56B9-B9B4-45D9-83CC-28531E47AD3FQ34235750-A6F0005E-4FBC-43EB-976E-139C4AD0BA5EQ34240314-81F09AF8-7F79-44FB-806D-D9F2D0F4958CQ34337660-E817C631-1EC7-4A43-84D4-4AEB84D9D7A9Q34355722-EEDBD978-3534-4DC4-A6EF-B1A227B30BD8Q34425519-F995F836-AF29-43A2-9B85-0D4123C37E85Q34590943-945097D7-D46E-4CB1-A6AE-29F519DE3BF0Q34760735-8D88E730-9F34-4050-85B5-3EBA8F858FA4Q35623324-F915178A-4D64-4F36-AE03-8167B5C9D7A8Q35717972-E3C323E3-04DD-4C01-831F-AEDC9D385434Q35986604-7CC87D27-BAA6-489D-A160-C6B781634CFEQ36138213-6A1D5599-7961-4EB6-8759-69BEB31BE1C2Q36264723-BFA6204F-B1EB-44B9-A62D-2621588207E9Q36307935-F922129D-3A54-49B0-97CD-778EC31FEFDAQ36572545-F633F8FD-8786-4656-AD96-CE462D410A07Q36816955-E1EA5C2E-0B01-4FAC-8002-1E1EC8AE50D8Q36817140-4FD96FC8-F1CB-43A8-9768-0F1FBD898364Q36822162-C8659C4E-0360-4A9A-AE2A-E889BDD44754Q36839872-DD014E0F-6A0B-4FF8-A173-01947EE449C3Q37063580-8912A6D7-296C-45FC-8DA3-921437A92957Q37103961-0EB187C7-5732-4591-9F81-12B8564389BBQ37146056-48F49175-D3D5-415D-B99D-2631A5ADBDD4Q37205598-B5E13F24-B0F7-421E-89E7-A07918D1FAEAQ37286985-7EB6B632-B0C9-4404-BBD7-435F11E64438Q37672032-C109C29E-E86F-4F01-A560-D6BB83D91A96Q37777048-915DFD82-5DE9-4759-BEDB-60FCBD432FA6
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
State-of-the-art therapeutics: Hodgkin's lymphoma.
@ast
State-of-the-art therapeutics: Hodgkin's lymphoma.
@en
type
label
State-of-the-art therapeutics: Hodgkin's lymphoma.
@ast
State-of-the-art therapeutics: Hodgkin's lymphoma.
@en
prefLabel
State-of-the-art therapeutics: Hodgkin's lymphoma.
@ast
State-of-the-art therapeutics: Hodgkin's lymphoma.
@en
P356
P1476
State-of-the-art therapeutics: Hodgkin's lymphoma.
@en
P304
P356
10.1200/JCO.2005.05.016
P407
P577
2005-09-01T00:00:00Z